Wealth Enhancement Advisory Services’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $197M | Buy |
183,702
+22,314
| +14% | +$22.8M | 0.33% | 45 |
|
|
2026
Q1 | $136M | Sell |
161,388
-52,598
| -25% | -$53.3M | 0.28% | 63 |
|
|
2025
Q4 | $228M | Buy |
213,986
+11,817
| +6% | +$11.3M | 0.31% | 54 |
|
|
2025
Q3 | $171M | Buy |
202,169
+14,238
| +8% | +$10.6M | 0.26% | 72 |
|
|
2025
Q2 | $147M | Buy |
187,931
+36,066
| +24% | +$28M | 0.24% | 79 |
|
|
2025
Q1 | $125M | Buy |
151,865
+13,693
| +10% | +$11.4M | 0.24% | 80 |
|
|
2024
Q4 | $107M | Sell |
138,172
-29,546
| -18% | -$24.5M | 0.2% | 100 |
|
|
2024
Q3 | $149M | Buy |
167,718
+10,665
| +7% | +$9.59M | 0.32% | 60 |
|
|
2024
Q2 | $142M | Buy |
157,053
+22,603
| +17% | +$18.1M | 0.34% | 56 |
|
|
2024
Q1 | $105M | Buy |
134,450
+10,800
| +9% | +$7.69M | 0.27% | 78 |
|
|
2023
Q4 | $72.1M | Buy |
123,650
+4,549
| +4% | +$2.66M | 0.21% | 107 |
|
|
2023
Q3 | $64M | Buy |
119,101
+79,986
| +204% | +$41.2M | 0.21% | 106 |
|
|
2023
Q2 | $18.3M | Sell |
39,115
-3,911
| -9% | -$1.64M | 0.2% | 58 |
|
|
2023
Q1 | $14.8M | Buy |
43,026
+9,706
| +29% | +$3.27M | 0.17% | 68 |
|
|
2022
Q4 | $11.3M | Buy |
33,320
+25,457
| +324% | +$9.03M | 0.15% | 82 |
|
|
2022
Q3 | $2.57M | Sell |
7,863
-8,751
| -53% | -$2.77M | 0.04% | 156 |
|
|
2022
Q2 | $5.49M | Buy |
+16,614
| New | +$4.99M | 0.08% | 122 |
|
|
2021
Q4 | – | Sell |
-22,750
| Closed | -$5.65M | – | 318 |
|
|
2021
Q3 | $5.65M | Sell |
22,750
-13,435
| -37% | -$3.32M | 0.08% | 103 |
|
|
2021
Q2 | $8.38M | Sell |
36,185
-15,426
| -30% | -$3.1M | 0.14% | 76 |
|
|
2021
Q1 | $9.43M | Buy |
51,611
+1,263
| +3% | +$247K | 0.17% | 66 |
|
|
2020
Q4 | $9.61M | Buy |
50,348
+18,640
| +59% | +$2.78M | 0.22% | 49 |
|
|
2020
Q3 | $4.9M | Buy |
31,708
+22,622
| +249% | +$3.5M | 0.13% | 62 |
|
|
2020
Q2 | $1.5M | Sell |
9,086
-27,244
| -75% | -$4.18M | 0.04% | 147 |
|
|
2020
Q1 | $5.71M | Buy |
36,330
+5,421
| +18% | +$745K | 0.2% | 54 |
|
|
2019
Q4 | $4.06M | Buy |
+30,909
| New | +$3.58M | 0.14% | 69 |
|
|
2019
Q3 | – | Sell |
-29,178
| Closed | -$3.17M | – | 220 |
|
|
2019
Q2 | $3.17M | Buy |
29,178
+16,428
| +129% | +$1.93M | 0.14% | 61 |
|
|
2019
Q1 | $1.5M | Sell |
12,750
-3,167
| -20% | -$385K | 0.08% | 99 |
|
|
2018
Q4 | $1.86M | Buy |
+15,917
| New | +$1.78M | 0.12% | 69 |
|
|
2017
Q4 | – | Sell |
-10,670
| Closed | -$929K | – | 160 |
|
|
2017
Q3 | $929K | Buy |
+10,670
| New | +$875K | 0.08% | 108 |
|
|
2017
Q2 | – | Sell |
-18,945
| Closed | -$1.59M | – | 170 |
|
|
2017
Q1 | $1.59M | Sell |
18,945
-18,567
| -49% | -$1.49M | 0.17% | 66 |
|
|
2016
Q4 | $2.76M | Buy |
37,512
+13,616
| +57% | +$1.01M | 0.33% | 46 |
|
|
2016
Q3 | $1.95M | Buy |
+23,896
| New | +$1.91M | 0.29% | 52 |
|
|
2016
Q2 | – | Sell |
-14,161
| Closed | -$1.03M | – | 122 |
|
|
2016
Q1 | $1.03M | Buy |
14,161
+640
| +5% | +$48.4K | 0.21% | 103 |
|
|
2015
Q4 | $1.14M | Buy |
+13,521
| New | +$1.12M | 0.29% | 57 |
|
Other funds holding LLY
SC
ONB
GIM
WAM
CRM
Wealth Enhancement Advisory Services's LLY Position: Q2 2026 in Review
Wealth Enhancement Advisory Services increased its Eli Lilly (LLY) stake by 14% in Q2 2026, buying an estimated $22.8M and bringing the position to 183,702 shares worth $197M. The position accounts for 0.33% of the portfolio, ranked #45.
Wealth Enhancement Advisory Services first reported a position in LLY in Q4 2015 and has held it in 34 quarters since. The position peaked at $228M in Q4 2025. 1,102 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Wealth Enhancement Advisory Services held 183,702 shares of Eli Lilly worth $197M as of Q2 2026.
- Wealth Enhancement Advisory Services bought 22,314 Eli Lilly shares in Q2 2026, an estimated $22.8M.
- Eli Lilly made up 0.33% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #45 holding.
- Wealth Enhancement Advisory Services first reported a position in Eli Lilly in Q4 2015 and has held it in 34 quarters since.
- Wealth Enhancement Advisory Services's Eli Lilly position peaked at $228M in Q4 2025.
- 1,102 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.